Patent: 9,273,031
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,273,031
Title: | Combination therapy with MDM2 and EFGR inhibitors |
Abstract: | Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. |
Inventor(s): | Errico; Joseph P. (Warren, NJ), Mugrage; Benjamin (Cranbury, NJ), Turchi; Ignatius (Yardley, PA), Sills; Matthew (Berkeley Heights, NJ), Ong; Jane (Franklin Park, NJ), Allocco; John (Staten Island, NY), Wines; Pam (Manalapan, NJ), Bastos; Margarita (Plainsboro, NJ) |
Assignee: | Errico; Joseph P. (Warren, NJ) |
Application Number: | 14/571,770 |
Patent Claims: | see list of patent claims |
Details for Patent 9,273,031
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | See Plans and Pricing | 2039-02-26 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | See Plans and Pricing | 2039-02-26 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | See Plans and Pricing | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |